ArticleCureus2025
Impact of Preoperative Embolization on Surgical Outcomes in Carotid Paraganglioma Resection: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective cohort study evaluates the impact of preoperative embolization (PE) on surgical outcomes in carotid paraganglioma resections. Carotid paragangliomas are rare, highly vascular tumors that pose significant surgical challenges due to their proximity to critical neurovascular structures. Although PE has been proposed to reduce intraoperative bleeding, operative time, and complications, its efficacy remains debated. Clinical records of 56 patients undergoing 63 resections between 2007 and 2021 at the Instituto De Seguridad Social Del Estado De México Y Municipios State Cancer Center were analyzed. Outcomes assessed included intraoperative bleeding, surgical time, hospital stay, cranial nerve and vascular complications, transfusion requirements, and late neurological sequelae. While embolization did not provide statistically significant benefits across the overall cohort, subgroup analysis revealed notable advantages in Shamblin III tumors. In this group, embolization was associated with reduced bleeding (223 mL vs. 550 mL, p=0.038), shorter operative time (146.7 min vs. 223 min, p=0.048), and decreased hospital stay (2.17 vs. 5.40 days, p=0.004). Vascular complications and late sequelae were also significantly lower in embolized Shamblin III cases (5.6% vs. 40%, p=0.043). No significant differences were observed in short-term neurological outcomes between embolized and non-embolized groups. These findings suggest that PE may offer surgical benefits in select high-risk patients, particularly those with advanced-stage tumors, while its routine use in Shamblin I and II cases appears unwarranted. Individualized decision-making based on tumor classification and surgical context remains essential to optimizing outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.